The proton pump inhibitor, omeprazole, surprisingly resulted in higher rates of proximal duodenal mucosal bicarbonate secretion than previously reported using an H2 receptor antagonist for gastric acid inhibition. Gastroduodenal perfusions were performed in healthy volunteers to evaluate whether this incidental finding is explained by more potent gastric acid inhibition by omeprazole or might be caused by the different mode of drug action. Basal and stimulated gastric and duodenal bicarbonate secretion rates were measured in the same subjects in control experiments (n= 17) and after pretreatment with high dose omeprazole (n= 17) and ranitidine (n=9) 
Abstract
The proton pump inhibitor, omeprazole, surprisingly resulted in higher rates of proximal duodenal mucosal bicarbonate secretion than previously reported using an H2 receptor antagonist for gastric acid inhibition. Gastroduodenal perfusions were performed in healthy volunteers to evaluate whether this incidental finding is explained by more potent gastric acid inhibition by omeprazole or might be caused by the different mode of drug action. Basal and stimulated gastric and duodenal bicarbonate secretion rates were measured in the same subjects in control experiments (n= 17) and after pretreatment with high dose omeprazole (n= 17) and ranitidine (n=9), respectively, by use of a technique permitting simultaneous measurements. Concentrations of bicarbonate were measured in the respective effluents by the method of back titration. Both omeprazole and ranitidine completely inhibited gastric acid secretion (pH 6 Previous work has shown the existence of a pH gradient at the luminal surface of the gastroduodenal mucosa generated by active secretion of bicarbonate into the mucus gel layer.1 2 As bicarbonate comprises the first line of defence against luminal acid and pepsin, recent research has focused on mucosal bicarbonate transport mechanisms both in experimental animals and in humans.3 The effect of various antiulcer drugs on gastroduodenal bicarbonate secretion has been investigated in several studies,4 among which a few have concentrated on the effect of the proton pump inhibitor, omeprazole. Administration of omeprazole to cats has resulted in both reduced5 and increased6 rates of gastric bicarbonate secretion, while duodenal mucosal bicarbonate secretion in cats7 and in rats8 seems unaffected. Although relevant for clinical use in the treatment of acid related disorders, the potential effect of proton pump inhibitors on human gastroduodenal mucosal bicarbonate secretion has not previously been considered.
Incidentally, we observed that omeprazole resulted in higher rates of basal and vagally stimulated proximal duodenal mucosal bicarbonate secretion than previously reported using ranitidine as an inhibitor of gastric acid. To evaluate whether this finding might be explained by more potent inhibition of gastric acid by omeprazole or by the different mode of drug action, gastric and duodenal bicarbonate secretion rates were determined by use of a technique permitting simultaneous measurements.8 The same healthy volunteers were studied in control experiments without acid inhibition and after administration of omeprazole and ranitidine, respectively, using supramaximal, equipotent doses sufficiently large to obtain total inhibition of gastric acid secretion. In supplementary experiments, the combination of omeprazole and ranitidine on basal duodenal mucosal bicarbonate secretion was studied.
Methods
Healthy volunteers Twenty one healthy volunteers (12 men and nine women, median age 32 years, range 24-50), with no history of gastrointestinal or other medical diseases, consented to the study protocol. None of the healthy volunteers had ingested aspirin, non-steroidal anti-inflammatory drugs, or alcohol during the week before entering the study, which was carried out according to the Helsinki II Declaration and approved by the ethics committee of Copenhagen and Frederiksberg.
Experimental design Three series of experiments were performed. In the first series eight volunteers had simultaneous gastric and proximal duodenal perfusions twice (isotonic saline) with an interval of at least one week. The perfusions were performed in random order, that is, as one set of control perfusions (without acid suppression for determination of acid secretion in the stomach and bicarbonate secretion in the duodenum) and one set of experimental perfusions (for determination of bicarbonate secretion in the stomach and the duodenum) prior to which the subject was pretreated with a 60 mg oral dose of omeprazole (Astra A/S, Albertslund, Denmark) once daily for three days and 80 mg intravenously one hour before perfusion.
In the second series of experiments nine other volunteers had gastric and proximal duodenal perfusion three times. The perfusions were performed in random order and included one set of control perfusions (without acid suppression) and two sets of experimental perfusions prior to which the subject was pretreated with omeprazole as described above or with a 900 mg oral dose of ranitidine (Glaxo Denmark A/S, Br0ndby, Denmark) 12 and two hours before the experiment and ranitidine 50 mg/h intravenously during perfusion.
Supramaximal doses of omeprazole and ranitidine were chosen to ensure the complete suppression of gastric acid secretion required for determination of gastric bicarbonate secretion.9 Each perfusion in the first and second series of experiments included a 60 minute equilibration period followed by a 30 minute basal period and a 60 minute sham feeding period. In the second series of experiments the duodenal bulb was acidified (HCI 0.1 M; 20 ml; 5 min) after the sham feeding period and then the duodenum was perfused for 45 minutes with isotonic saline. Attempts to measure gastric bicarbonate secretion after acidification of the stomach failed, because it was impossible to remove all the instilled acid within 30 minutes.
In the third series of experiments another four healthy volunteers had proximal duodenal perfusion once to study the effect of the combination of omeprazole and ranitidine. Each subject was pretreated with omeprazole as described above and after a 60 minute equilibration period the duodenum was perfused during basal conditions for 60 minutes. Then a 50 mg intravenous bolus injection of ranitidine was given. After a 30 minute equilibration period the duodenum was perfused for another 60 To determine the contamination of the 
Results

Validation of methods
The mean recovery of the gastric and duodenal markers were 82 (2)% and 86 (2)%, respectively, with no differences between control, omeprazole, and ranitidine experiments. Values ofbasal and stimulated gastric and duodenal fluid outputs, in addition to recoveries of phenol red, [51Cr] and trypsin, showed no significant differences (p>0 3) between the groups. Only a small amount of gastric contents entered the duodenum (0.3 (0. 1)%, that is 0.01 mlmin). The duodenogastric reflux equalled 0-8 (0-2)%, that is 0-06 mlmin. The contents of trypsin in the duodenal effluents were 0O6 (0.2)% of the average minimum trypsin output from the pancreas14 and a total of 11 samples from five subjects containing :25 ,ug/ml, 3%/o were excluded.
pH Measurements Total inhibition of gastric acid secretion was achieved both after omeprazole and ranitidine administration and there was no significant difference between gastric pH values (p=0.8; Table I ). The duodenal pH measurements showed no significant (p>0 7) differences between control, omeprazole and ranitidine experiments, respectively (Table I) .
Gastric acid and bicarbonate secretion
In control experiments basal and vagally stimulated gastric acid secretion was 4.2 (1 1) mmol/h and 7 9 (1.7) mmol/h, respectively.
The basal rates of gastric bicarbonate secretion were 401 (56) pumol/h and 500 (104) ,umol/h after ranitidine and omeprazole administration, respectively. The difference was not statistically significant (p>0 05; Table II 
